DEXYCU (dexamethasone intraocular suspension) 9%.
Pre-clinicalCompleted 0 watching 0 views this weekπ€ Quiet
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cataract
Conditions
Cataract
Trial Timeline
Nov 13, 2019 β May 1, 2020
NCT ID
NCT04290676About DEXYCU (dexamethasone intraocular suspension) 9%.
DEXYCU (dexamethasone intraocular suspension) 9%. is a pre-clinical stage product being developed by EyePoint Pharmaceuticals for Cataract. The current trial status is completed. This product is registered under clinical trial identifier NCT04290676. Target conditions include Cataract.
Hype Score Breakdown
Clinical
5
Activity
2
Company
5
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04290676 | Pre-clinical | Completed |
Competing Products
20 competing products in Cataract